OBJECTIVES: Levosimendan is a novel inotropic agent claimed to improve myocardial contractility by a calcium-sensitizing effect. Our aim was to evaluate dose-dependent effects of levosimendan on left ventricular (LV) contractility and energetic properties in an acute, ischaemic heart failure porcine model.
INTRODUCTION
Acute heart failure following heart surgery is usually treated by administration of inotropic substances such as beta-adrenergic agonists and phosphodiesterase-inhibiting drugs. Classical inotropes increase the contractile force at the expense of increased oxygen consumption, namely by increasing cyclic adenosine phosphate and the transport of calcium into the cytosol [1] . A new inotropic substance, levosimendan (SIMDAX ® , Orion Corporation, Espoo, Finland), was suggested to have a dual mode of action, inducing increased inotropy [2, 3] and vasodilatation at the same time [2, 4] . Levosimendan has been found to increase the heart's inotropic state by sensitizing the myofilaments to calcium [3, 5, 6] . This mechanism of augmented contractility is proposed to be less oxygen-consuming than the mechanisms by which beta-adrenergic agonists and phosphodiesterase-inhibiting drugs act. However, in vitro studies have shown that when the dose of levosimendan is increased, a phosphodiesterase 3 (PDE3)-inhibitory effect becomes more pronounced [3, 7, 8] .
The clinical setting we envisioned when designing the study was acute postcardiotomy generalized myocardial failure due to poor myocardial protection or microembolization (air, ascending aortic atherosclerosis). However, the heart failure model may also be applicable for post-percutaneous coronary intervention heart failure, as microembolization is thought to be an important contributor to this as well.
In order to investigate the effect of levosimendan on haemodynamics, myocardial mechanical work and oxygen consumption, we designed a dose-response study and compared the effects of different doses of levosimendan on the left ventricle (LV) and the vascular system in a pig model of acute ischaemic heart failure. In addition, mitochondrial respiration in the myocardial cells and the relative distribution of the total LV energy consumption on mechanical and non-mechanical work were analysed [9] . We hypothesized that when increasing the dose of levosimendan in an acute heart failure model, less oxygen-efficient mechanisms of inotropy (i.e. a PDE3-inhibitory effect) would be activated.
MATERIALS AND METHODS
The experimental protocol was approved by the local steering committee of the Norwegian Experimental Animal Board. All animals received humane care in compliance with the European Convention on Animal Care. Six pigs (Sus scrofa domesticus, Norwegian strain) of female gender, weight 30-40 kg, were habituated to the animal facilities over 3-7 days and fasted overnight with free access to water. We used an anaesthetized open-chest pig model, as described earlier [10] .
Anaesthesia and medication
At the day of the experiment, the animals were pre-medicated with intramuscular injection of ketamine (20 mg/kg) and azaperone (5 mg/kg). Anaesthesia was induced by intravenous injection of ketamine (250 mg), atropine (1 mg), pentobarbital-sodium (250 mg) and fentanyl (250 µg). Throughout the experiment the pigs were given a continuous infusion of fentanyl (0.02 mg/kg/h) and midazolam (0.4 mg/kg/h). After the surgical preparation, the animals were given 2500 IU of heparin to avoid clotting of catheters. To prevent arrhythmias, they also received a bolus of amiodarone (300 mg in 50 ml NaCl 0.9% i.v. over 20 min). A bolus of hexamethonium chloride (600 mg in 50 ml NaCl 0.9% over 20 min i.v.) was given to block autonomic reflex influences on haemodynamics. Circulating volume was maintained throughout the experiment by a continuous infusion of Ringer's acetate. At the end of the experiment, the animals were sacrificed by injection of a lethal dose injection of pentobarbital.
Surgical instrumentation
After tracheostomy, the pigs were intubated and mechanically ventilated with 60% oxygen. Ventilator settings were adjusted according to blood-gas analysis (PaCO 2 4-6 kPa). The jugular veins were catheterized for infusions and measurement of central venous pressure (CVP) and the bladder was drained through a cystostomy. Arterial pressure was continuously measured through a catheter inserted into the descending thoracic aorta from one of the femoral arteries. From the same femoral artery catheter, blood samples were drawn for measurements of blood gas and blood resistivity (rho (ρ)). The heart was exposed through a median sternotomy and the left hemiazygos vein was ligated at its passage through the pericardium. Cardiac output (CO) was measured continuously by means of a transit time (MediStim AS, Oslo, Norway) flow probe (16 mm) on the pulmonary artery. Transit time flow probes were also placed on the left anterior descending (LAD), circumflex (Cx) and right coronary arteries for determination of coronary blood flow. The great cardiac vein was catheterized through the superior caval vein via the coronary sinus so that myocardial venous blood from the LV could be sampled. For preload alterations, a rubber band was looped around the inferior caval vein. Furthermore, to adjust for parallel conductance by the hypertonic saline technique, a catheter was inserted into the main pulmonary trunk through the right ventricular wall. Finally, a dual-field, combined pressure-conductance (CD leycom, The Netherlands) catheter was advanced to the LV cavity via the left carotid artery. Fluoroscopy confirmed the proper placement of the catheter. Importantly, the animals were stabilized for 30 min before any measurements. The instrumentation described here has earlier been thoroughly described in the literature [10] .
Experimental protocol
Animals were allowed 30 min of stabilization after surgery. After baseline measurements, the microembolization technique was applied to induce acute LV failure [10] . Polystyrene microspheres with a diameter of 55 μm were dissolved in 0.9% NaCl to a concentration of 1 mg microspheres per millilitre. A catheter was placed in the main stem of the left coronary artery under fluoroscopic guidance. LV failure was induced by repeated injections of 2.5-5.0 mg boluses every 5 min until a stable 30% reduction of CO was achieved. Levosimendan was infused following induction of heart failure in increasing dose as outlined below.
Haemodynamic data were sampled at six time points: baseline values (B), after heart failure induction (F) and after each of the four different dose levels of levosimendan (D1-D4). Myocardial biopsies from the LV were taken to assess the mitochondrial respiration at four measurement times: B, F, D2 and D4.
Levosimendan infusion
In general guidelines from Orion Pharma, a loading dose of 6-12 µg/kg of levosimendan infused over 10 min and then a continuous dose of 0.1 µg/kg/min is recommended. The patient response should be assessed, and the infusion rate could be decreased to 0.05 or increased to 0.2 µg/kg/min depending on the clinical response. In our study, levosimendan infusion started immediately after induction of heart failure. The first and the last dose intervals were intended to give a concentration level, respectively, well below and well above the recommended clinical blood concentrations. The second and the third dose intervals aimed at approximating the minimum and maximum blood concentrations used clinically. As T1/2 for levosimendan is about 60 min, approximately 270 min infusion time would be required to achieve steady state. It was found impractical to infuse levosimendan over such a long time period in our open-chest pig model. Instead, we infused the dose necessary to achieve steady state over a 30 min period. Clearance was set to zero and from D2 to D4, the amount of levosimendan given in advance was subtracted from the infusion dose. This resulted in the following regime-D1: 2.5 µg/kg, D2: 10 µg/kg, D3: 40 µg/kg, D4: 80 µg/kg. Each level of levosimendan infusion was kept for 30 min and the recordings were performed in the last 10 min (described above).
Biopsy sampling
After surgical preparation and exposure of the heart (at time point B), one biopsy was taken from the LV myocardium in the area between apex and base (BioPince™ needle, Angiotech Pharmaceuticals, Inc, Vancouver, Canada). Biopsies were put into ice-cold solution S (see below) for further treatment within 10 min. Further in a similar manner, three biopsies were sampled at F, D2 and D4.
Mitochondrial respiration
Mitochondrial respiration was studied in situ in saponinpermeabilized fibres as described by Veksler and colleagues [11] and reviewed in detail recently [12] . Briefly, fibres were gently separated using small forceps (Dumont #5) under binocular microscope in solution S at 4°C, and then permeabilized in the same solution with 50 µg/ml saponin for 30 min at 4°C while shaking. After being rinsed for 10 min in solution S at 4°C and then in solution R at 22°C under shaking, the skinned fibres were transferred to a water-jacketed oxygraphic cell (Strathkelvin Instruments, Glasgow, UK) equipped with a Clark electrode containing 3 ml of solution R. Solutions R and S contained 2.77 mM CaK2EGTA, 7.23 mM K2EGTA (100 nM free Ca 2+ ), 6.56 mM MgCl 2 (1 mM free Mg 2+ ), 20 mM taurine, 0.5 mM dithiothreitol, 50 mM potassium-methane sulphonate (160 mM ionic strength) and 20 mM imidazole ( pH 7.1 at 22°C). Solution S also contained 5.7 mM Na 2 ATP, 15 mM creatine-phosphate, while solution R contained 5 mM glutamate, 2 mM malate, 3 mM phosphate and 2 mg/ml bovine serum albumin. Basal respiration rate (V 0 ) was measured at 22°C under continuous magnet stirring in the oxygraphic cells. Maximal ADP-stimulated respiration above V 0 was measured by the addition of 2 mM ADP as phosphate acceptor and the maximal respiration rate (V max ) was calculated as (V 0 + V ADP ).
Conductance catheter technique
Evaluation of intraventricular pressure and volume with the conductance catheter technique has been described in the literature in detail [13] . In principle, a pressure-conductance catheter is placed in the LV. The catheter yields simultaneous real-time intraventricular pressure and volume, thus generating instantaneous pressure-volume loops. The volume is calculated from the time-varying electrical conductance which is linearly proportional to the blood volume in the ventricle. Measurements have to be calibrated by deducting the volume related to conductance of the adjacent myocardium ( parallel conductance (Vp)) and a calibration factor called slope factor α that compares the stroke volume (SV) of the conductance catheter to a second, independently measured SV. The commonly used formula for the time-varying LV volume (V(t)) was published by Baan et al. [13] :
in which G(t) is the sum of the conductances, σ b is the blood conductivity (the inverse property of blood resistivity rho (ρ) measured by a calibrating cuvette) and L is the inter-electrode distance.
Data acquisition and analysis
Conductance catheter data formed the basis for the calculation of haemodynamic indices as described in detail elsewhere [10, 14] . These measurements consisted of arterial blood samples for assessment of blood resistivity (ρ) and haemoglobin (Hb). Parallel conductance was estimated by injection of hypertonic 10% NaCl into the pulmonary artery with simultaneous LV pressure-volume sampling. From the conductance alterations induced by intraventricular hypertonic saline, parallel volume was calculated as described elsewhere [10, 13] . Respiratory influence on haemodynamics was avoided by disconnecting the respirator during file-sampling. In order to assess contractility, pressure-volume data were recorded during transient (minimum 10 s) preload reduction by vena cava occlusion. A series of pressure-volume assessments with simultaneous myocardial oxygen consumption (MVO 2 ) recording were then performed at five different steady-state preload reductions in order to assess the PVA-MVO 2 relationship, as described elsewhere [9, 10] . Pressurevolume area (PVA, in mmHg × ml) represents the total mechanical work and MVO 2 is the calculated LV oxygen consumption, as described by Suga [9] . The PVA-MVO 2 relationship represents the LV energy conversion efficiency. Pressure-volume data were recorded while simultaneous Cx and LAD coronary blood flow were assessed and a blood sample for oxygen saturation measurement was drawn from the coronary sinus. Arterial haemoglobin and oxygen saturation were assessed at uninfluenced preload. In the end, a linear regression of the different points of PVA and MVO 2 obtained gave the PVA-MVO 2 relationship. The conductance and pressure signals were sampled, digitized and stored in a desktop computer connected to the Leycom Sigma 5 DF (CD Leycom). LV contractile performance was assessed by preload recruitable stroke work (PRSW) and by the rate of LV pressure increase during isovolaemic contractions (dP/dt max ). PRSW is the linear relationship between stroke work and end-diastolic volume recorded during vena cava occlusion recordings [15] . The slope of this relationship (Mw) is a contractility index which is less sensitive to load conditions than dP/dt max . Myocardial diastolic function was assessed by dp/dt min , τ and the enddiastolic pressure-volume relationship (EDPVR). General haemodynamic values, such as CO, CVP, middle artery pressure (MAP), heart rate (HR), etc., were also noted. The assessment of diastolic and systolic function has been explained in detail elsewhere [14, 15] .
Statistical analyses
Calculations were performed using a spreadsheet (Microsoft Office Excel 2003). All statistical tests were performed in SPSS 17.0. Variables are presented as mean ± standard deviation (SD). We performed one-Sample Kolmogorov-Smirnov test to assess whether the residuals in the linear mixed model were consistent with a normal distribution for the error term. After having confirmed a normality distribution of a variables' residual, we used a linear mixed model to calculate the P-value between each levels/measurement times. P-values < 0.05 were considered significant.
BASIC SCIENCE RESULTS
Pig body weights and LV weights were 34.3 ± 4.0 kg and 113.3 ± 13.3 g, respectively. General haemodynamic data, ventricular mechanics and LV mechanoenergetics at all measurement times are presented in Tables 1-3 . CO, systemic vascular resistance (SVR), HR and Mw at all measurement times and maximal mitochondrial respiration at B, F, D2 and D4 are illustrated in Figs. 1-3 .
Embolization with microparticles in our model was successful in inducing profound heart failure. This was reflected by a statistically significant reduction in important parameters of myocardial pump function; CO, MAP, stroke work (SW) and Mw. After microembolization and stabilization, infusion of levosimendan produced dose-dependent changes in some of the study parameters. A vasodilatation was experienced, reflected by a significant dose-dependent reduction in SVR and MAP. Ventricular contractility indices (Mw and dP/dt max ) were not in line with each other: Mw was not affected by levosimendan infusion while dP/dt max improved significantly (at D4). At the lowest dose levels of the levosimendan infusion, only the b EDPVR parameter had any statistical significant change. The maximal mitochondrial respiration was reduced after induction of LV failure and thereafter unchanged throughout the total infusion time.
DISCUSSION
In this study, we investigated dose-dependent effects of levosimendan in an open-chest pig model of acute heart failure. We were unable to detect a true increase in myocardial contractility at any dose level of levosimendan. At a low dose of the agent, only the diastolic parameter b EDPVR was affected. Chronotropy and vasodilatory effects were found at higher dose levels. An increase in CO at the highest dose level (80 µg/kg) of levosimendan infusion was one of our main findings. Furthermore, our results contradict the hypothesis that levosimendan at a high dose uses more energy demanding mechanisms of inotropy than levosimendan at lower doses.
It is challenging to study the effect of levosimendan on myocardial contractility in clinical studies due to concomitant medication with other inotropes and the lack of reliable markers of myocardial contractility under these circumstances. We chose an openchest pig model to be able to isolate the effects of different doses of levosimendan on the failing LV. The well-validated method of conductance catheter measurements was used. Because levosimendan is often used clinically in the setting of ischaemic heart failure, we induced acute ischaemic heart failure in our experimental animals by microparticle embolization into the main stem of the left coronary artery. This method is thoroughly described and validated previously [10] . Published literature suggests that the haemodynamic effects of levosimendan in pigs are similar to the effects reported in humans. Although one could argue that the chosen model does not resemble acute regional ischaemia, we believe that the model is clinically relevant, because it is similar to postcardiotomy low-output failure as a result of generalized myocardial dysfunction as a result of prolonged aortic cross-clamp time, air or particulate embolization (ascending aortic atherosclerosis). With the main goal of understanding levosimendan's mechanisms of action further, we calculated and assessed different systolic and diastolic indices and we analysed the relationship between myocardial oxygen consumption and mechanical energy of the LV at sub-therapeutic, therapeutic and supra-therapeutic levels of the agent in this setting. Although a similar experimental model of acute heart failure was described previously [2] , no experimental evaluation of the effects of different doses of levosimendan on myocardial contractility in an embolization heart failure model has yet been published. Following embolization, a 29% reduction in CO and a 31% decrease in MAP compared with baseline values, indicated that heart failure was induced. This was confirmed by impaired systolic function represented by a reduction in dP/dt max and Mw (both P < 0.05). Additionally, a 20% reduction in myocardial maximal mitochondrial respiration (P < 0.05) was found. Changes in diastolic properties after microembolization were demonstrated by decreased LV compliance and decreased isovolaemic relaxation rate (indicated by increased b EDPVR and decreased dP/ dt min , both P < 0.05).
We found a statistically significant reduction in MAP and SVR (both P < 0.05) after levosimendan infusion in our study. This is in line with the literature. Levosimendan is a well-known vasodilator [2, 16] in which the mechanisms have been described earlier [4] .
In accordance with several studies in the literature [2, 17, 18] , we conclude that levosimendan increased CO in our study: CO was significantly increased at the highest dose level D4 (P < 0.05). In contrast, SV was not increased at any dose level. This lack of improvement in SV may possibly be explained by a reduced filling of the ventricle, as presented by the reduced end-diastolic pressure (EDP) at D4. In view of this, the increase in CO was an effect of the increased HR.
Levosimendan has been found to improve cardiac contractility in several studies [2, 3] . In the present study, we calculated contractility indexes using the conductance catheter technique: dP/dt max had a statistically significant increase of 26% at D4 compared with F (P < 0.05), while Mw had no significant increase in any of the infusions intervals compared with F. Increased dP/ dt max is also reported in a study with anaesthetized pigs with ischaemic heart by Tassini et al. [2] . It has to be kept in mind that an increase in dP/dt max may be related to augmented preload and does not reflect a true increase in contractility in all circumstances. In our experiments, the most reliable index of contractility (Mw) was not influenced by levosimendan, thus we conclude that levosimendan had no effect on contractility in the setting of acute heart failure in our anaesthetized open-chest pig model.
Few studies have investigated levosimendan's influence on myocardial efficiency, and the results are contrasting and difficult to interpret. In our study, the slope of the PVA-MVO2 relationship did not change at any dose levels of levosimendan infusion. In view of this, we conclude that levosimendan did not affect contractile efficiency at any dose level in our model. In contrast to the slope, the y-axis intercept ('the unloaded MVO2) of the linear PVA-MVO2 relationship was changed by the levosimendan infusion. The unloaded MVO2 increased from F to D1 and somewhat surprisingly decreased at larger dose intervals (all P < 0.05). Our data may suggest that a low dose of levosimendan given to a failing heart induces an increased energy use for calcium-handling (EC coupling) and metabolic processes, while higher doses of levosimendan results in decreased energy expenditure for these non-mechanical processes. Levosimendan has been proposed to exert different modes of action at low and high doses [3, 7, 8] . An increasing degree of PDE-inhibition has been suggested at higher doses. This would have implied an increased oxygen waste with increasing doses. This was not found in our study.
In conclusion, our results contradict the hypothesis that levosimendan at a high dose employs more energy demanding mechanisms of inotropy (e.g. phosphodiesterase inhibition) than levosimendan at lower dose. Possibly supporting our results, Ukkonen et al. [16] has presented neutral effects of levosimendan on LV efficiency in patients with congestive heart failure. However, material and methods differ a lot between this and our study. In contrast to our results, Pagel et al. [19] have presented results suggesting increased myocardial efficiency after levosimendan infusion. Furthermore, Banfor et al. have presented no increase in myocardial oxygen consumption of levosimendan compared with dobutamine at inotropic concentrations in dogs [20] . However, these studies differ a lot from our experimental animal setup regarding study design and method of estimating the myocardial efficiency. In contrast to the results by Pagel et al. suggesting improved metabolic efficiency when infusing high doses of levosimendan, Müller et al. demonstrated a significant increase in oxygen consumption related to mechanical work when increasing the dose of levosimendan to supra-therapeutic levels [17] . Tassani et al. [2] have studied the efficiency of the myocardial performance after levosimendan infusion following obstruction of a coronary artery in an anaesthetized open-heart pig model. In the hypoperfused area, a combination of decreasing power index and increasing lactate release contradict improved myocardial efficiency. Different effects of levosimendan within the myocardium (between intact and hypoperfused myocardium) found by Tassani et al. may explain why studies including hearts with normal function have presented results contrasting to studies including hearts with post-ischaemic function when assessing its efficiency after levosimendan infusion [17, 19] . It is possible that the distribution or ratio of ischaemic versus non-ischaemic myocardium in our study may have affected our conclusion of the functional effects of levosimendan.
Only a few investigators have analysed the in vivo effects of levosimendan on diastolic properties. Investigating the impact on diastolic properties is important, as calcium sensitizers may theoretically impair relaxation. In the present study, LV compliance seems to be improved (b EDPVR is reduced (P < 0.05)) with the two lowest doses of levosimendan. This effect is stable throughout the infusion of gradually higher doses of levosimendan. In contrast, the isovolaemic relaxation rate was at no infusion-level affected by the levosimendan infusion (both dP/ dt min and τ were unchanged). In other studies, it is presented a somewhat surprising decrease in the time constant of relaxation after levosimendan infusion [21] .
In recent investigations, levosimendan is shown to affect mitochondrial function by means of both preconditioning and postconditioning. Opening of ATP-dependent K + channels is the mechanism described to yield this cardioprotection. Theoretically, opening of ATP-dependent K + channels could affect mitochondrial respiration [22] . This could contribute to improved cardiac function by levosimendan, as reported in clinical studies. To our knowledge, the present study is the first to study maximal mitochondrial respiration in biopsies from the LV after levosimendan infusion in a pig model of acute ischaemic heart failure. The myocardial maximal mitochondrial respiration decreased following heart failure induction in our study, similar to findings of Zoll et al. [23] who describe a 20% reduction of the maximal respiration in the myocardial mitochondria after 45 min of ischaemia, induced by left descending coronary artery ligation in pigs. Our results could thus be expected according to the mitochondrial structural and functional injuries occurring early in the process of ischaemia [24] . The decline in mitochondrial respiration was not improved by levosimendan infusion throughout the experiment.
A limitation of our study is the use of an acute animal model which made it necessary to infuse higher doses within a shorter time-interval than standard clinical doses. It would have been interesting to investigate the effect of levosimendan following prolonged infusion. However, we believe that our model is clinically very relevant for the setting of acute unexpected postcardiotomy myocardial failure. Knowledge on the benefits and shortcomings of acute levosimendan infusion is important to guide the clinician through different steps of treatment including mechanical assist systems.
In view of our results, it may have been beneficial to have a control group without levosimendan. However, changes in other parameters such as diastolic values, SVR and CO did indicate effective blood concentrations of levosimendan. Besides, our study was designed primarily as a dose-response study in which we aimed at studying dose-dependent effects of levosimendan. Moreover, the animal model used has been validated extensively in previous studies [10] . Thus, it seems unlikely that a control group would have made any difference to the main findings of the study. Furthermore, we chose not to provide any other inotropic agent or vasopressors because the aim of our research was to study the isolated effects of levosimendan on the cardiovascular system.
We conclude that levosimendan in an anaesthetized openchest pig model of acute heart failure mainly induced vasodilatation, increased HR and improved CO. Our results did not confirm a true increase in contractility or energy saving effect. Furthermore, our results did not support the hypothesis that a less oxygen-efficient mechanism of inotropy (a PDE3-inhibitory effect) would be activated when increasing the dose of levosimendan.
